These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 39207624)

  • 1. Comparative Efficacy of Colchicine and Intensive Low-density Lipoprotein Cholesterol Lowering in Patients with Atherosclerotic Diseases receiving Statins: A Network Meta-analysis of Randomized Controlled Trials.
    Ou Z; Wang F; Chen Y; Liu X; Ran B; Yin Y; Cui K
    Cardiovasc Drugs Ther; 2024 Aug; ():. PubMed ID: 39207624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
    Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials.
    Lee M; Cheng CY; Wu YL; Lee JD; Hsu CY; Ovbiagele B
    JAMA Neurol; 2022 Apr; 79(4):349-358. PubMed ID: 35188949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More- Versus Less-Intensive Lipid-Lowering Therapy.
    Toyota T; Morimoto T; Yamashita Y; Shiomi H; Kato T; Makiyama T; Nakagawa Y; Saito N; Shizuta S; Ono K; Kimura T
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005460. PubMed ID: 31412729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
    BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
    Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S
    Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.
    Khan SU; Yedlapati SH; Lone AN; Hao Q; Guyatt G; Delvaux N; Bekkering GET; Vandvik PO; Riaz IB; Li S; Aertgeerts B; Rodondi N
    BMJ; 2022 May; 377():e069116. PubMed ID: 35508321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis.
    Khan SU; Khan MU; Virani SS; Khan MS; Khan MZ; Rashid M; Kalra A; Alkhouli M; Blaha MJ; Blumenthal RS; Michos ED
    Eur J Prev Cardiol; 2022 Feb; 28(18):2001-2009. PubMed ID: 33624058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative Effect of Current Intensive Lipid-Lowering Drugs on Cardiovascular Outcomes in Secondary Prevention　- A Meta-Analysis of 12 Randomized Trials.
    Wang S; Xiu J; Liao W; Liao Y; Bin J
    Circ J; 2019 May; 83(6):1356-1367. PubMed ID: 31006730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
    Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC
    PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
    Kereiakes DJ; Lepor NE; Gerber R; Veronica Lee L; Elassal J; Thompson D; Michael Gibson C
    Atherosclerosis; 2018 Oct; 277():211-218. PubMed ID: 30025648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified.
    Baum SJ; Wade RL; Xiang P; Arellano J; Cerezo Olmos C; Nunna S; Chen CC; Carter CM; Desai NR
    Ther Clin Risk Manag; 2019; 15():1325-1332. PubMed ID: 32009789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
    Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Daly DD; DePalma SM; Minissian MB; Orringer CE; Smith SC
    J Am Coll Cardiol; 2017 Oct; 70(14):1785-1822. PubMed ID: 28886926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease.
    Leiter LA; Hegele RA; Brown V; Bergeron J; Mackinnon ES; Mancini GBJ
    Rev Cardiovasc Med; 2024 May; 25(5):190. PubMed ID: 39076473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Different Low-Density Lipoprotein-Lowering Medications on Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients With Diabetes Mellitus.
    Saag JL; Gross D; Stirt D; Espina Rey A; Gros B
    Cureus; 2023 Jun; 15(6):e40905. PubMed ID: 37492827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.